Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Compound trial record
Compound · clinical trials

NOAC clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our Germany, Denmark, Spain, Italy, Netherlands, Poland, Switzerland, Canada, Australia, UK, USA, France, Japan, Israel, Sweden, Czechia, Turkey, Mexico, Belgium, India, Brazil, South Korea, China and Norway registers that name NOAC as an intervention. Synced 9 Nov 2026
6Current trials
4Recruiting now
6Lead sponsors
24Country registers
At a glance

NOAC is named as an intervention in 6 current clinical trials in our Germany, Denmark, Spain, Italy, Netherlands, Poland, Switzerland, Canada, Australia, UK, USA, France, Japan, Israel, Sweden, Czechia, Turkey, Mexico, Belgium, India, Brazil, South Korea, China and Norway registers. 4 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Abbott Medical Devices (1). The most-studied condition is Atrial Fibrillation.

Patient leaflets for NOAC

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting467%
  • Active, closed233%

Trials by phase

  • Not applicable350%
  • Phase 4350%
01

Clinical trials of NOAC

6 trials
StudyPhaseStatusLead sponsorRegisters
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
NCT03968393 · Stroke, Atrial Fibrillation
Phase 4 Recruiting Population Health Research Institute India, Germany, Spain, Italy, Netherlands, Sweden, Denmark, Switzerland, Canada, Brazil, South Korea, Australia
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
NCT06013020 · ClinicalTrials.gov ↗ · STEMI - ST Elevation Myocardial Infarction
Phase 4 Recruiting Zunyi Medical College China
Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
NCT06212674 · ClinicalTrials.gov ↗ · Ischemic Stroke, Atrial Fibrillation
Phase 4 Recruiting Medical University of Silesia Poland
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
NCT03642509 · ClinicalTrials.gov ↗ · Atrial Fibrillation, Stroke
Not applicable Recruiting University of Aarhus Germany, Sweden, Denmark, Norway
Amplatzer Amulet LAAO vs. NOAC
NCT04226547 · Atrial Fibrillation, Stroke, Bleeding
Not applicable Active, closed Abbott Medical Devices UK, USA, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Switzerland, Czechia, Turkey, Canada, Mexico, Japan, Australia, Israel
CHAMPION-AF Clinical Trial
NCT04394546 · Atrial Fibrillation, Stroke, Bleeding
Not applicable Active, closed Boston Scientific Corporation UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Canada, Japan, Australia, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with NOAC

5 conditions
Atrial Fibrillation5Stroke4Bleeding2STEMI - ST Elevation Myocardial Infarction1Ischemic Stroke1
05

Related compounds

06

Questions about NOAC trials

How many clinical trials are testing NOAC?

6 current trials in our Germany, Denmark, Spain, Italy, Netherlands, Poland, Switzerland, Canada, Australia, UK, USA, France, Japan, Israel, Sweden, Czechia, Turkey, Mexico, Belgium, India, Brazil, South Korea, China and Norway registers name NOAC as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are NOAC trials recruiting patients?

Yes. 4 of the 6 trials are recruiting: 2 with sites in Germany, 2 with sites in Denmark, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Canada, 1 with sites in Australia, 2 with sites in Sweden, 1 with sites in India, 1 with sites in Brazil, 1 with sites in South Korea, 1 with sites in China and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors NOAC clinical trials?

Abbott Medical Devices (1), Boston Scientific Corporation (1), Population Health Research Institute (1) and Zunyi Medical College (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how NOAC works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NOAC works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NOAC (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.